PMID- 35486013
OWN - NLM
STAT- MEDLINE
DCOM- 20220503
LR  - 20220503
IS  - 1000-0607 (Print)
IS  - 1000-0607 (Linking)
VI  - 47
IP  - 4
DP  - 2022 Apr 25
TI  - [Clinical efficacy and safety evaluation of acupuncture combined with moxibustion 
      in treatment of allergic rhinitis].
PG  - 336-42
LID - 10.13702/j.1000-0607.20210315 [doi]
AB  - OBJECTIVE: To evaluate the clinical efficacy and safety of acupuncture combined 
      with moxibustion on allergic rhinitis. METHODS: Using the random number table, 80 
      patients with allergic rhinitis were divided into a medication group and an 
      acupuncture combined with moxibustion (acu-mox) group, 40 cases in each one. In 
      the medication group, ioratadine tables were prescribed for oral administration, 
      one tablet daily for 10 days as 1 session , 3 sessions of treatment were 
      required. In the acupuncture combined with moxibustion group, bilateral Yingxiang 
      (LI20), Yintang (EX-HN3), bilateral Hegu (LI4) and bilateral Shenshu (BL23) were 
      selected as the main points and stimulated with acupuncture and moxibustion; and 
      the acupoint prescription was modified according to symptoms. This combined 
      treatment was given once every day, stimulating for 30 min each time, and 10 
      treatments made 1 course, for 3 courses of treatment totally. Before and after 
      treatment, the scores for symptoms and physical signs, as well as the score of 
      rhino-conjunctivitis related quality of life scale (R-QOL) were evaluated 
      separately. The sample of the inferior turbinate mucosa tissue was collected and 
      the distribution of eosinophil (EOS) was scored using HE staining and Sheldeny 
      evaluation. Using enzyme-linked immunosorbent assay (ELISA), the contents of 
      serum immunoglobulin E (IgE), retinoic-acid-receptor-related orphan nuclear 
      receptor gammat (RORgammat), forkhead box protein P3 (Foxp3), interleukin-17 (IL-17), 
      IL-27 and IL-33 were determined. The clinical efficacy was evaluated in the 
      patients with allergic rhinitis of two groups and all the adverse reactions were 
      recorded during treatment. RESULTS: The scores of symptoms and physical signs as 
      well as the score of R-QOL, and EOS distribution score and the contents of serum 
      IgE, RORgammat, IL-17 and IL-33 were all reduced as compared with those before 
      treatment in each group (P<0.05), and the contents of serum Foxp3 and IL-27 were 
      increased as compared with those before treatment in each group (P<0.05). After 
      treatment, the scores of symptoms and physical signs as well as the score of 
      R-QOL, and the contents of serum IgE, RORgammat and IL-33 in the acu-mox group were 
      lower than those in the medication group (P<0.05), and the contents of serum 
      Foxp3 and IL-27 were higher than those of the medication group (P<0.05). The 
      total effective rate of the acu-mox group was 100.0% (40/40), significantly 
      higher than 82.5% (33/40) in the medication group (P<0.05). No ob-vious adverse 
      reaction was found in either group during and after treatment. CONCLUSION: 
      Acupuncture combined with moxibustion is significantly effective and safe in 
      treatment of allergic rhinitis. Its effect mechanism may be related to the 
      balance modulation of Th1/Th2 and Th17/Treg cells mediated by naive CD4(+)T 
      cells.
FAU - Ma, Wei
AU  - Ma W
AD  - College of Acupuncture-Moxibustion and Tuina, Hunan University of Chinese 
      Medicine, Changsha 410208, China; Preventive Treatment Center, Yulin Hospital of 
      Chinese Medicine, Yulin 719000, Shaanxi Province.
FAU - Zhai, Chun-Tao
AU  - Zhai CT
AD  - The Third Clinical College, Shanxi University of Chinese Medicine, Taiyuan 
      030024.
FAU - Shang, Hui-Mei
AU  - Shang HM
AD  - Preventive Treatment Center, Yulin Hospital of Chinese Medicine, Yulin 719000, 
      Shaanxi Province.
FAU - Xu, Xiao-Shan
AU  - Xu XS
AD  - The Third Clinical College, Shanxi University of Chinese Medicine, Taiyuan 
      030024.
FAU - Zheng, Tong
AU  - Zheng T
AD  - Preventive Treatment Center, Yulin Hospital of Chinese Medicine, Yulin 719000, 
      Shaanxi Province.
FAU - Tian, Yue-Feng
AU  - Tian YF
AD  - The Third Clinical College, Shanxi University of Chinese Medicine, Taiyuan 
      030024.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhen Ci Yan Jiu
JT  - Zhen ci yan jiu = Acupuncture research
JID - 8507710
RN  - 0 (Forkhead Transcription Factors)
RN  - 0 (Interleukin-17)
RN  - 0 (Interleukin-27)
RN  - 0 (Interleukin-33)
RN  - 0 (Nuclear Receptor Subfamily 1, Group F, Member 3)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - *Acupuncture Therapy
MH  - Forkhead Transcription Factors
MH  - Humans
MH  - Immunoglobulin E
MH  - Interleukin-17
MH  - *Interleukin-27
MH  - Interleukin-33
MH  - *Moxibustion
MH  - Nuclear Receptor Subfamily 1, Group F, Member 3
MH  - Quality of Life
MH  - *Rhinitis, Allergic/therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Acupuncture combined with moxibustion
OT  - Allergic rhinitis
OT  - Clinical efficacy
OT  - Safety evaluation
EDAT- 2022/04/30 06:00
MHDA- 2022/05/04 06:00
CRDT- 2022/04/29 10:27
PHST- 2022/04/29 10:27 [entrez]
PHST- 2022/04/30 06:00 [pubmed]
PHST- 2022/05/04 06:00 [medline]
AID - 10.13702/j.1000-0607.20210315 [doi]
PST - ppublish
SO  - Zhen Ci Yan Jiu. 2022 Apr 25;47(4):336-42. doi: 10.13702/j.1000-0607.20210315.